Angiotensin Receptor Blockers and Cognition: a Scoping Review
View Full Paper
Ask AI
Bookmark
Share
Key result
ARBs may lower dementia and cognitive decline risk versus other antihypertensives, particularly ACE inhibitors.
Why the study?
To provide an overview of the association between angiotensin II receptor blocker use and cognitive outcomes.
Does angiotensin II receptor blocker use prevent cognitive decline and dementia in adults with hypertension or cardiovascular disease?
Comparison
ARB use vs other anti-hypertensive classes or ACEis
Design
Scoping review
Authors
Discussion
Loading...
Member takes
Implication
Supports ARB preference for cognitive risk reduction in hypertension; leaves open confirmation in randomized trials before practice change.
Structured PICO
Does angiotensin II receptor blocker use prevent cognitive decline and dementia in adults with hypertension or cardiovascular disease?
P
Population
Adults and elderly patients with hypertension, cardiovascular disease, or at risk of cognitive decline and dementia
I
Intervention
Angiotensin II receptor blockers (ARBs) as a class
C
Comparator
Other anti-hypertensive classes (including ACE inhibitors), placebo, or no anti-hypertensive medication
O
Outcome
Cognitive outcomes including incident dementia, Alzheimer's disease, vascular dementia, and cognitive decline
ARBs may offer superior neurocognitive protection compared to other antihypertensives like ACE inhibitors, highlighting their potential as an adjunctive approach for neuroprotection.
Limitations
- Inconsistency of historical evidence from observational studies and early randomized trials
- Much of the mechanistic evidence comes from animal and laboratory studies
- Lack of high-quality evidence from large-scale, long-term prospective randomized controlled trials
- Inconsistent results across previous epidemiological studies
- Mechanisms underlying the role of ARBs in dementia and cognition decline remain inadequately understood
- Need for future long-term randomized trials to yield more definitive results
Cite This Study
Zhou et al. (2023) conducted a review in Dementia and cognitive decline. Angiotensin II receptor blockers (ARBs) vs. ACE inhibitors and other anti-hypertensive medications was evaluated on Cognitive outcomes and incident dementia. Angiotensin II receptor blockers may provide greater neuroprotection and lower the risk of dementia and cognitive decline compared to other anti-hypertensive classes, particularly ACE inhibitors.
Topics
View Full Paper
Ask AI
Bookmark
Share